Jeffrey H Schwartz
Overview
Explore the profile of Jeffrey H Schwartz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
1083
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bae C, Aiello L, Hawks J, Kaifu Y, Lindal J, Martinon-Torres M, et al.
Evol Anthropol
. 2023 Nov;
33(1):e22011.
PMID: 37943093
No abstract available.
2.
Schwartz J, Smith E
Cancer Rep (Hoboken)
. 2022 Sep;
5(10):e1670.
PMID: 36052764
Background: Prenatally identified suprarenal masses are most often found to be adrenal hemorrhage. The most common tumor in this situation is neuroblastoma. Case Presentation: We report the case of a...
3.
Schwartz J, Pantoja-Perez A, Arsuaga J
Anat Rec (Hoboken)
. 2021 Jun;
305(8):1991-2029.
PMID: 34166582
Circum-nasal and nasal cavity morphology add to the picture of the Sima de los Huesos specimens as, at one level, representing a distinct morph and, at another, displaying individual variation....
4.
Schwartz J
Mitochondrial DNA A DNA Mapp Seq Anal
. 2021 Apr;
32(4):126-151.
PMID: 33818247
The tenets underlying the use of mtDNA in phylogenetic and systematic analyses are strict maternal inheritance, clonality, homoplasmy, and difference due to mutation: that is, there are species-specific mtDNA sequences...
5.
Niss O, Lorsbach R, Berger M, Chonat S, McLemore M, Buchbinder D, et al.
Blood Cells Mol Dis
. 2021 Jan;
87:102534.
PMID: 33401150
Congenital dyserythropoietic anemias (CDAs) are characterized by ineffective erythropoiesis and distinctive erythroblast abnormalities; the diagnosis is often missed or delayed due to significant phenotypic heterogeneity. We established the CDA Registry...
6.
Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk J, Velazquez E, et al.
JACC Heart Fail
. 2020 Dec;
9(2):115-123.
PMID: 33309574
Objectives: Tafamidis is an effective treatment for transthyretin amyloid cardiomyopathy (ATTR-CM), this study aimed to determine whether there is a differential effect between variant transthyretin amyloidosis (ATTRv) and wild-type transthyretin...
7.
Hanna M, Damy T, Grogan M, Stewart M, Gundapaneni B, Patterson T, et al.
Am J Cardiol
. 2020 Nov;
141:98-105.
PMID: 33220323
In the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial, tafamidis significantly reduced all-cause mortality and cardiovascular-related hospitalizations in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). ATTR-CM is associated with a significant burden...
8.
Damy T, Garcia-Pavia P, Hanna M, Judge D, Merlini G, Gundapaneni B, et al.
Eur J Heart Fail
. 2020 Oct;
23(2):277-285.
PMID: 33070419
Aims: Tafamidis is an effective treatment for transthyretin amyloid cardiomyopathy (ATTR-CM) in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT). While ATTR-ACT was not designed for a dose-specific assessment, further...
9.
10.
Huber P, Flynn A, Sultan M, Li H, Rill D, Ebede B, et al.
Amyloid
. 2019 Jul;
26(4):203-209.
PMID: 31353964
Tafamidis is approved in over 40 countries to delay neurologic progression in patients with transthyretin amyloid polyneuropathy (ATTR-PN). A comprehensive, integrated analysis of safety data from interventional, observational and surveillance...